Sepsis Global Market Report 2025

The sepsis market size has grown strongly in recent years. It will grow from $0.93 billion in 2024 to $1.02 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to the increasing incidence of sepsis due to aging populations, the rising prevalence of chronic diseases, greater awareness of sepsis among healthcare providers, escalating healthcare expenditures, and the implementation of government initiatives for early detection and management.

The sepsis market size is expected to see strong growth in the next few years. It will grow to $1.44 billion in 2029 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to the increasing adoption of artificial intelligence in critical care, the rising prevalence of multidrug-resistant infections, growing awareness campaigns about sepsis, expanding healthcare infrastructure in emerging economies, and increasing investments in biotechnology and pharmaceutical research. Major trends in the forecast period include the development of rapid point-of-care diagnostics, the adoption of AI-driven predictive analytics, personalized antibiotic stewardship programs, advancements in blood culture techniques, innovative biomarker identification, and the development of novel therapies targeting immune modulation.

The growing prevalence of infectious diseases is expected to drive the expansion of the sepsis market in the coming years. Infectious diseases, caused by bacteria, viruses, fungi, or parasites, can spread through direct contact, contaminated sources, or insect vectors. Common examples include tuberculosis, influenza, ringworm, and malaria. Several factors contribute to the increasing incidence of infectious diseases, including globalization, environmental changes, drug-resistant pathogens, and gaps in healthcare systems. Sepsis, a severe complication of infections, results from the body's extreme response, leading to widespread inflammation and potential organ failure. For example, in November 2024, the Centers for Disease Control and Prevention reported that the United States recorded 9,633 cases of tuberculosis (TB) in 2023, marking a 15.6% increase from the 8,332 cases reported in 2022. Consequently, the rising burden of infectious diseases is fueling the growth of the sepsis market.

Companies in the sepsis market are leveraging advanced technology, such as artificial intelligence (AI)-powered platforms, to improve early diagnosis, enhance treatment precision, and predict patient outcomes. These innovations aim to reduce mortality rates and enhance healthcare efficiency in managing sepsis. For instance, in June 2024, Predicate Healthcare Performance Group (HPG), a US-based healthcare company, launched OpenDX, an AI-powered diagnostic platform integrating wearable biosensors to detect early signs of sepsis. This technology aids in sepsis diagnosis and has the potential for application in other medical conditions, highlighting the increasing role of AI in diagnostics. Predicate’s chest sensor enables healthcare professionals to identify early indicators of sepsis, a condition that is often challenging to diagnose.

In April 2024, Prenosis Inc., a US-based biotechnology research company, partnered with Roche Holding AG to advance sepsis diagnosis and management through AI-driven technology. As part of the partnership, Roche will distribute Prenosis’ Sepsis ImmunoScore, an AI-based medical software designed to assist healthcare providers in rapidly diagnosing sepsis and predicting adverse outcomes. This collaboration enhances clinical sepsis management by integrating AI technology into healthcare settings. Roche Holding AG is a Switzerland-based pharmaceutical company specializing in oncology, immunology, infectious diseases, and other medical fields.

Major players in the sepsis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck KGaA, Bayer AG, Thermo Fisher Scientific Inc., Abbott laboratories, Novartis AG, Siemens AG, Asahi Kasei Corporation, Becton, Dickinson and Company, bioMérieux SA, QuidelOrtho Corporation, Diasorin S.p.A., Innoviva Inc., Seegene Inc., EKF Diagnostics, Boditech Med Inc., Cytovale Inc., Alifax S.r.l., Hansa Biopharma, Amomed Pharma GmbH, Inotrem S.A., Abionic SA, Biosystems Inc., Immunexpress Inc.

North America was the largest region in the sepsis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sepsis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sepsis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Sepsis is a life-threatening condition resulting from the body's extreme response to an infection. It occurs when the immune system releases chemicals into the bloodstream to combat the infection, but these chemicals trigger widespread inflammation, leading to tissue damage, organ failure, and potentially death.

The primary aspects of sepsis management include diagnosis and therapeutics. Diagnosis focuses on detecting sepsis through various tests and procedures that identify infections and assess their severity. The condition can be caused by pathogens such as bacteria, viruses, and fungi. Sepsis-related applications include severe sepsis and septic shock, with utilization in hospitals, pathology labs, and reference laboratories.

The sepsis market research report is one of a series of new reports that provides sepsis market statistics, including the sepsis industry's global market size, regional shares, competitors with a sepsis market share, detailed sepsis market segments, market trends and opportunities, and any further data you may need to thrive in the sepsis industry. This sepsis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The sepsis market includes revenues earned by entities by providing services such as blood culture testing, molecular diagnostics, biomarker testing, intravenous (IV) fluid management, organ support services, and tele-ICU services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.